BioBusiness

The US and pharmerging markets will drive growth in drug spending; number of approvals to increase.

Company to focus on innovation, growth, and productivity with creation of new units.

Orphan and cancer drugs continue to lead, but treatments for many common diseases were also approved in 2018.

Drug pricing and reimbursement concerns will continue to hinder industry growth in 2019, according to data and analytics company GlobalData.

Merger cites combined strengths in oncology, immunology and inflammation, and cardiovascular disease.

Pricing pressures, investment volatility, and government disfunction greet Biopharma in 2019.

Compensation and professional challenges are key pieces to solving the biopharma employee satisfaction puzzle.

Bio/pharma companies are successfully launching novel therapies; however, the industry still needs to work on manufacturing innovation.

The proposed $12.7-billion deal includes the spinoff of GSK and Pfizer consumer brands to a new UK-listed company.

More-and earlier-interaction between R&D and payers will be essential if innovative therapies are to become more accessible for patients, and more profitable for manufacturers, said panelists at the 2018 Galien Foundation Forum.

Survey results and record attendance may show positive signs for established and emerging biopharma regions.

The maturation of single-use technologies presents commercial bioprocessing options for small-volume drug products.

While food, shelter, and clothing are the primal essentials for life, hope-as embodied by modern medicine-has now become part of that human expectation.

The company announced it is creating a new Primary Care global business unit and a China & Emerging Markets unit.

More than 120 healthcare organizations plan to bring competition to generic drug market.

Sharing of bioprocessing know-how can help resolve pressing industry problems.

Alcami and the University of North Carolina Wilmington received a grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals to prepare students for careers in pharmaceutical sciences.

Girish Malhotra argues in CPhI Annual Report that shorter approval times and financial incentives are needed to promote manufacturing improvements.

Preliminary survey results rank the United States, Germany, and Japan as tier-one nations for bioprocessing performance and potential.

Pharmaceutical scientist association announces upcoming term’s board of directors.

Drug product approval from FDA follows previous approvals from European and Japanese authorities.

The Alliance for Regenerative Medicine’s (ARM) report highlights major trends and metrics from the 2018 second quarter in the regenerative medicines sector.

Frustrated by slow market adoption, Gottlieb maps out new plan for biosimilar competition.

In launching FDA’s Biosimilar Action Plan, Gottlieb takes innovator companies to task for delaying competitive biosimilar products.

Moderna’s new manufacturing plant in Norwood, MA gives the company capacity for preclinical and Phase I and II clinical manufacturing for its mRNA development candidates, including personalized cancer vaccines.

CPhI Korea to feature zone for finished dosage formulation drug products.

Pfizer creates separate business units for innovator medicines, generic drugs, and consumer products.

Report predicts PAT, NIRS, continuous bioprocessing, and a ‘technological arms race’ could improve biopharma manufacturing efficiencies.

This article highlights 15 years of changes in biopharmaceutical manufacturing.

After 30 years of biologic-drug advances, the industry and patients still have a lot to learn.